Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow IN8BIO, INC.

Get SEC filing alerts via email and in your feed for IN8BIO, INC.

INAB

IN8BIO, INC.

About IN8BIO, INC.

IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer and autoimmune diseases. Its proprietary DeltEx platform enables ex vivo expansion, genetic engineering, and scalable manufacturing of allogeneic, autologous, and iPSC-derived T cells. The company focuses on innovative immunotherapies, including T cell engagers, targeting solid and hematologic cancers to improve patient outcomes and achieve durable remissions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from IN8BIO, INC.

1
1
IN8BIO, INC. IN8bio Reports Q1 2026 Financial Results with $5.1 Million Net Loss

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
IN8BIO, INC. IN8bio Reports $19.4 Million Net Loss and Operational Updates in Annual Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
IN8BIO, INC. IN8Bio Reports Improved Q3 2025 Financial Results with $3.9 Million Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
IN8BIO, INC. IN8Bio Reports Improved Financial Results with Reduced Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
IN8BIO, INC. IN8BIO Reports $5.6 Million Net Loss in Q1 2025, Focuses on INB-100 Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
IN8BIO, INC. IN8bio Reports $30.4 Million Net Loss for 2024, Cash Position Declines to $11.1 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
IN8BIO, INC. IN8bio Reports Significant Financial Challenges, Net Loss of $7.1M in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments